RxDoctor Payments Data

Hisham Keblawi, MD

Obstetrics & Gynecology · Huntington, WVNPI 1922144120

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 43.0% of the total. Reporting peaked in 2024 at $482 and has fallen 70.7% since, to $141 in 2025.

$1,150in general payments, 2019–2025

Across 68 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$494
  • AstraZeneca$257
  • Paratek Pharmaceuticals, Inc.$110
  • Lilly USA, LLC$73
  • Shield Therapeutics Inc$62
  • Teva Pharmaceuticals USA, Inc.$37
  • plus $117 from 6 others
$168,311in research payments, 2019–2025

Across 51 payments — averaging $3300.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$168K

What the payments were for

  • Food & beverage$1,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,150 in reported general payments places this provider in the 60th percentile of 172 obstetrics & gynecology providers in West Virginia.

See all obstetrics & gynecology providers in West Virginia

Medicare billing

Part B allowed, 2024
$4,052
Medicare patients
40
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DottiEstradiol13$815
Estradiol14$429
Terconazole15$409
Clobetasol Propionate16$228

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →